Imberti Davide, Mastroiacovo Daniela
Internal Medicine Department, Piacenza Hospital, Haemostasis and Thrombosis Center, Piacenza, Italy.
Angiology Unit, SS Filippo and Nicola Hospital, Avezzano, AQ, Italy.
Intern Emerg Med. 2017 Aug;12(5):561-563. doi: 10.1007/s11739-017-1688-7. Epub 2017 Jun 24.
In the Hokusai-VTE trial, 733 patients were treated with the reduced dose edoxaban regimen, which maintained efficacy and safety compared with the 60 mg dose, and was safer than warfarin. The prophylactic doses of apixaban and rivaroxaban reduced the risk of recurrent venous thromboembolism (VTE) in the extended treatment trials. Dabigatran 110 mg was approved by the European Medicine Agency for VTE treatment. Further data from registries and real-world studies will help to clarify whether patients, with other specific characteristics, can benefit from the reduced dose of direct oral anticoagulants.
在葛西-VTE试验中，733例患者接受了依度沙班低剂量方案治疗，该方案与60毫克剂量相比，疗效和安全性得以维持，且比华法林更安全。在延长治疗试验中，阿哌沙班和利伐沙班的预防剂量降低了复发性静脉血栓栓塞（VTE）的风险。达比加群110毫克已获欧洲药品管理局批准用于VTE治疗。来自登记处和真实世界研究的进一步数据将有助于阐明其他具有特定特征的患者是否能从直接口服抗凝剂的低剂量中获益。
